Regarding “Cardiovascular Outcomes Following Major Gastrointestinal Bleeding in Patients With Pre-Existing Cardiovascular Disease: The INTERBLEED International Prospective Cohort Study”
I read with great interest the INTERBLEED prospective cohort study by Forbes et al,1 which represents one of the most rigorously designed prospective evaluations of cardiovascular outcomes following gastrointestinal bleeding (GIB) in patients with pre-existing cardiovascular (CV) disease. The finding that antithrombotic resumption between 4 and 7 days after GIB was associated with reduced odds of major adverse CV events (MACE) is clinically compelling. That said, I believe several methodologic considerations deserve attention before these findings are applied in clinical practice.
